Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISION 2: Olaparib in HRD+ Advanced Cancers
NCT03967938Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in cancer, sponsored by AstraZeneca. Started Feb 2019; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03967938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03967938.